BackgroundThe current Danish National Guideline (DNG) for treatment of pyogenic vertebral osteomyelitis (PVO) recommends 6 weeks antibiotic (AB) treatment, with a 2-week intravenous (IV) AB lead-in followed by 4 weeks oral AB for uncomplicated PVO, and 12 weeks AB treatment with a 4-week IV AB lead-in followed by 8 weeks oral AB for complicated PVO.The… Continue reading Early shift to oral #antibiotic treatment for pyogenic vertebral #osteomyelitis (SAVE): study protocol for an open label, non-inferiority, nation-wide randomized controlled clinical trial
Tag: Antibiotics
Discovery of Late Intermediates in #Methylenomycin Biosynthesis Active against Drug-Resistant Gram-Positive #Bacterial Pathogens
The methylenomycins are highly functionalized cyclopentanone antibiotics produced by Streptomyces coelicolor A3(2). A biosynthetic pathway to the methylenomycins has been proposed based on sequence analysis of the proteins encoded by the methylenomycin biosynthetic gene cluster and the incorporation of labeled precursors. However, the roles played by putative biosynthetic enzymes remain experimentally uninvestigated. Here, the biosynthetic… Continue reading Discovery of Late Intermediates in #Methylenomycin Biosynthesis Active against Drug-Resistant Gram-Positive #Bacterial Pathogens
Monoclonal #antibodies protect against pandrug-resistant #Klebsiella pneumoniae
The ‘silent pandemic’ caused by antimicrobial resistance requires innovative therapeutic approaches. Human monoclonal antibodies (mAbs), which are among the most transformative and safe drugs in oncology1 and autoimmunity2, are rarely used for infectious diseases and not yet used for antimicrobial resistance3. Here we applied an antigen-agnostic strategy to isolate extremely potent human mAbs against Klebsiella… Continue reading Monoclonal #antibodies protect against pandrug-resistant #Klebsiella pneumoniae
The effect of commonly used non- #antibiotic medications on #antimicrobial resistance development in #Escherichia coli
Antimicrobial resistance (AMR) poses a global threat to public health. While antibiotic overuse is a primary driver, emerging evidence suggests that non-antibiotic medications (NAMs) may also contribute. This concern is particularly relevant in residential aged care facilities (RACFs), where both NAMs and antibiotics are frequently used. We investigated whether nine commonly used NAMs in RACFs,… Continue reading The effect of commonly used non- #antibiotic medications on #antimicrobial resistance development in #Escherichia coli
#Antibiotics damage the #colonic mucus barrier in a #microbiota-independent manner
Antibiotic use is a risk factor for development of inflammatory bowel diseases (IBDs). IBDs are characterized by a damaged mucus layer, which does not separate the intestinal epithelium from the microbiota. Here, we hypothesized that antibiotics affect the integrity of the mucus barrier, which allows bacterial penetrance and predisposes to intestinal inflammation. We found that… Continue reading #Antibiotics damage the #colonic mucus barrier in a #microbiota-independent manner
#Antibiotic-driven #dysbiosis in early life disrupts indole-3-propionic acid production and exacerbates #allergic airway inflammation in adulthood
•Early-life antibiotics increase the risk of allergy in adulthood•Antibiotics cause short-term disruption of the microbiome and systemic metabolome•Dysfunctional mitochondria in the airway epithelium lead to exaggerated inflammation•Indole-3-propionic acid counters the detrimental effects of early-life antibioticsSummaryAntibiotic use in early life disrupts microbial colonization and increases the risk of developing allergies and asthma. We report that mice… Continue reading #Antibiotic-driven #dysbiosis in early life disrupts indole-3-propionic acid production and exacerbates #allergic airway inflammation in adulthood
#Antibiotics Not Associated with Shorter Duration or Reduced Severity of Acute Lower #Respiratory Tract Infection
BackgroundAntibiotic use remains common for the treatment of lower respiratory tract infections. The objective of this study was to evaluate the impact of antibiotic use on the duration and severity of acute lower respiratory tract infection (LRTI).ParticipantsAdult patients presenting to US primary or urgent care sites with a chief complaint of cough and symptoms consistent… Continue reading #Antibiotics Not Associated with Shorter Duration or Reduced Severity of Acute Lower #Respiratory Tract Infection
Short Oral Antibiotic Therapy for Pediatric Febrile #Urinary Tract Infections: A Randomized Trial
Febrile urinary tract infection (fUTI) in well-appearing children is conventionally treated with a standard 10-day course of oral antibiotic. The objective of this study is to determine the noninferiority (5% threshold) of a 5-day amoxicillin-clavulanate course compared with a 10-day regimen to treat fUTIs.METHODSThis is a multicenter, investigator-initiated, parallel-group, randomized, controlled trial. We randomly assigned… Continue reading Short Oral Antibiotic Therapy for Pediatric Febrile #Urinary Tract Infections: A Randomized Trial
Prenatal antibiotic exposure, asthma and the atopic march: A systematic review and meta-analysis
BackgroundAntibiotic use during pregnancy may increase the risk for asthma in children. We performed a meta-analysis assessing prenatal antibiotic exposure and the risk for childhood wheeze or asthma, as well as for diseases associated with the atopic march. MethodsA systematic literature search protocol (PROSPERO-ID: CRD42020191940) was registered and searches were completed using Medline, Proquest, Embase,… Continue reading Prenatal antibiotic exposure, asthma and the atopic march: A systematic review and meta-analysis
2 Medical News 